HC Wainwright Estimates Altimmune's Q3 Earnings (NASDAQ:ALT)

Key Points

• HC Wainwright has raised its Q3 2025 earnings estimates for Altimmune from ($0.33) to ($0.26) per share, maintaining a "Buy" rating with a price target of $12.00.
• Despite varied analyst opinions, with some rating the stock as a "strong sell," Altimmune has a consensus rating of "Moderate Buy" and a price target of $17.40.
• In its latest earnings report, Altimmune exceeded market expectations by reporting ($0.27) earnings per share, compared to the consensus estimate of ($0.32).

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Investment analysts at HC Wainwright lifted their Q3 2025 earnings estimates for shares of Altimmune in a research note issued on Wednesday, August 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.26) per share for the quarter, up from their previous estimate of ($0.33). HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for Altimmune's current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Altimmune's Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.06) EPS, Q1 2026 earnings at ($0.31) EPS, Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.25) EPS, FY2027 earnings at ($1.27) EPS, FY2028 earnings at ($0.09) EPS and FY2029 earnings at $1.27 EPS.

Other equities research analysts have also recently issued research reports about the stock. B. Riley reduced their price objective on shares of Altimmune from $20.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday, August 13th. UBS Group reduced their price objective on shares of Altimmune from $26.00 to $24.00 and set a "buy" rating for the company in a research note on Wednesday, August 13th. William Blair reiterated a "market perform" rating on shares of Altimmune in a research note on Friday, June 27th. JMP Securities reduced their price objective on shares of Altimmune from $25.00 to $15.00 and set a "market outperform" rating for the company in a research note on Thursday, July 10th. Finally, Wall Street Zen upgraded shares of Altimmune from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $17.40.

Altimmune Stock Up 0.3%

Shares of ALT traded up $0.01 during mid-day trading on Friday, hitting $3.63. The company's stock had a trading volume of 2,218,988 shares, compared to its average volume of 3,770,638. The company's 50-day moving average is $4.64 and its 200-day moving average is $5.23. Altimmune has a 52-week low of $2.90 and a 52-week high of $11.16. The firm has a market capitalization of $320.37 million, a price-to-earnings ratio of -3.08 and a beta of -0.01. The company has a current ratio of 20.44, a quick ratio of 20.44 and a debt-to-equity ratio of 0.09.

Altimmune (NASDAQ:ALT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.05. Altimmune had a negative net margin of 438,730.03% and a negative return on equity of 62.63%. The firm had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.00 million.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. B. Riley Wealth Advisors Inc. acquired a new position in Altimmune during the 2nd quarter valued at approximately $71,000. Headlands Technologies LLC acquired a new position in Altimmune during the 2nd quarter valued at approximately $72,000. Tower Research Capital LLC TRC increased its stake in Altimmune by 234.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 14,956 shares of the company's stock valued at $58,000 after purchasing an additional 10,490 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of Altimmune by 108.5% in the second quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company's stock worth $39,000 after acquiring an additional 5,253 shares during the period. Finally, Brevan Howard Capital Management LP increased its stake in shares of Altimmune by 204.1% in the second quarter. Brevan Howard Capital Management LP now owns 133,209 shares of the company's stock worth $516,000 after acquiring an additional 89,405 shares during the period. Institutional investors and hedge funds own 78.05% of the company's stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.